Germline genetic association on efficacy of Immune-checkpoint inhibition in Metastatic Melanoma patients

被引：0
|
作者：
Ouwerkerk, W. [1 ]
Chielie, S. [1 ]
Bekkenk, M. [1 ]
Van Doorn, R. [2 ]
Blank, C. U. [3 ]
Haanen, J. B. [3 ]
Hospers, G. A. [4 ]
Kirchhoff, T. [5 ]
Luiten, R. [1 ]
机构：
[1] Amsterdam UMC, Amsterdam, Netherlands
[2] LUMC, Leiden, Netherlands
[3] NKI, Amsterdam, Netherlands
[4] Univ Med Ctr Groningen, Groningen, Netherlands
[5] NYU Langone Hlth, New York, NY USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2022年 / 142卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
485
引用
收藏
页码：S264 / S264
页数：1
相关论文
共 50 条
  • [41] Inhibition of TGFβ enhances immune-checkpoint blockade
    Diana Romero
    Nature Reviews Clinical Oncology, 2018, 15 : 201 - 201
  • [42] Tumour burden and efficacy of immune-checkpoint inhibitors
    Dall'Olio, Filippo G.
    Marabelle, Aurelien
    Caramella, Caroline
    Garcia, Camilo
    Aldea, Mihaela
    Chaput, Nathalie
    Robert, Caroline
    Besse, Benjamin
    NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (02) : 75 - 90
  • [43] Proteomic Markers of Immune-checkpoint Inhibitorrelatedd Toxicities in Melanoma
    Sierra-Davidson, K.
    Mehta, A.
    Bai, X.
    Frederick, D.
    Kasumova, G. G.
    Kim, M.
    Rucevic, M.
    Sallman-Almen, M.
    Rosenberg, L. Hultin
    Lieb, D.
    Hacohen, N.
    Flaherty, K.
    Sullivan, R.
    Boland, G. M.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S176 - S176
  • [44] Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?
    D'Abreo, Nina
    Adams, Sylvia
    NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (07) : 399 - 400
  • [45] Tumour burden and efficacy of immune-checkpoint inhibitors
    Filippo G. Dall’Olio
    Aurélien Marabelle
    Caroline Caramella
    Camilo Garcia
    Mihaela Aldea
    Nathalie Chaput
    Caroline Robert
    Benjamin Besse
    Nature Reviews Clinical Oncology, 2022, 19 : 75 - 90
  • [46] Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?
    Nina D’Abreo
    Sylvia Adams
    Nature Reviews Clinical Oncology, 2019, 16 : 399 - 400
  • [47] Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma
    Murakami, Naoka
    Borges, Thiago J.
    Yamashita, Michifumi
    Riella, Leonardo V.
    CLINICAL KIDNEY JOURNAL, 2016, 9 (03): : 411 - 417
  • [48] Association of efficacy and immune-related adverse events (irAEs) in patients with NSCLC receiving immune-checkpoint inhibitors (ICIs)
    Riudavets Melia, M.
    Gabriela Sullivan, I.
    Barba Joaquin, A.
    Anguera Palacios, G.
    del Carpio, L. P.
    Molto Valiente, C.
    Camacho Arellano, S. D.
    Moron Asensio, S.
    Gomila Pons, P.
    Andres Granyo, M.
    Castillo Villegas, D.
    Facundo Molas, C.
    Garcia Planella, E.
    Gonzalez Blanco, C.
    Barnadas Molins, A.
    Gich Saladich, I.
    Majem Tarruella, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 509 - 509
  • [49] Efficacy of LNS8801 in melanoma patients with prior immune-related adverse events from immune-checkpoint inhibitors
    Cohen, J. V.
    Garyantes, T. K.
    Muller, C.
    Natale, C. A.
    Orloff, M.
    Patel, S.
    Rodon, J.
    Shoushtari, A. N.
    ANNALS OF ONCOLOGY, 2024, 35 : S746 - S746
  • [50] Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: a systematic review
    Rossi, Ernesto
    Schinzari, Giovanni
    Maiorano, Brigida Anna
    Esposito, Ilaria
    Acampora, Anna
    Romagnoli, Jacopo
    Di Stefani, Alessandro
    Del Regno, Laura
    Lancellotta, Valentina
    Fionda, Bruno
    Tagliaferri, Luca
    Peris, Ketty
    Tortora, Giampaolo
    IMMUNOTHERAPY, 2022, 14 (01) : 65 - 76
12345